At the Grand Challenges Annual Meeting 2026 in London, a clear and urgent theme emerged: Africa’s future in biotechnology will be defined not by a shortage of ideas, but by how effectively those ideas are translated into real-world impact.

Bio Usawa was proud to participate in this global convening of leaders across science, industry, philanthropy, and public health. Representing the organization, CEO and President Dr. Menghis Bairu joined a panel discussion focused on strengthening Africa’s R&D ecosystem and building globally competitive biotechnology capabilities.

A central insight from the discussion was the need to move beyond discovery and place greater emphasis on the systems that convert research into tangible outcomes—products, companies, and sustainable industries.

As Dr. Bairu emphasized: “Africa has no shortage of ideas; our opportunity is to speed the pace of turning discoveries into products. We need to invest in translational research, product development infrastructure, skilled talent, IP systems, and long-term financing. Success should be measured by products reaching patients, not just publications.”

This perspective underscores a critical shift in how progress is defined. Scientific excellence remains essential, but it must be matched by the infrastructure, investment, and coordination required to bring innovations to market and to the patients who need them most.

The conversation also highlighted the importance of scaling biotechnology through more integrated approaches—moving from isolated projects to coordinated platforms supported by regional manufacturing, strong partnerships, and predictable demand.

While challenges persist, the broader outlook is one of opportunity and momentum. Africa’s expanding scientific talent base, evolving regulatory landscape, and growing commitment to addressing its own health priorities provide a strong foundation for long-term growth.

For Bio Usawa, the takeaway is clear: building a thriving biotechnology ecosystem requires sustained commitment - not only to discovery, but to the full continuum of innovation. Turning research into products, and products into enduring industrial capability, will define the next chapter of impact.